Communication Bridge™-2(CB2):针对轻中度原发性进行性失语症患者交流障碍的言语-语言干预的NIH 2期随机对照试验
CB2是一项2期、优效性、单盲、随机、平行组、主动对照的行为学临床试验,通过远程医疗模式对90例经临床确诊的原发性进行性失语症(PPA)患者随机分配至Communication Bridge™组(基于交流参与治疗模式的二元干预,采用显著训练刺激)或对照组(基于损伤治疗模式的非二元干预,针对词语提取和语言产生,采用固定刺激)。主要结局为交流信心和参与度,其他结局包括训练词语和脚本的准确性。参与者将在12个月内完成两个治疗阶段,并在基线、每个治疗阶段及入组后12个月测量结局。
要点
- CB2试验将提供2级证据,评估通过远程医疗模式实施的Communication Bridge™干预对轻中度PPA患者的疗效。
- 试验随机分配90例经临床确诊的PPA患者至Communication Bridge™组或对照组。
- 主要结局为交流信心和参与度,其他结局包括训练词语和脚本的准确性。
核心结论
- CB2试验将提供关于Communication Bridge™干预通过远程医疗模式对轻中度PPA患者疗效的2级证据。
- 该试验数据可用于评估两种言语-语言干预对PPA患者的疗效,有助于理解干预为何有效及对谁有效,从而推进PPA言语-语言干预的有效性试验。
研究设计与样本
- CB2是一项2期、优效性、单盲、随机、平行组、主动对照的行为学临床试验,通过远程医疗模式实施。
- 计划纳入90例经仔细表征且临床确诊的PPA患者,随机分配至两个言语-语言干预组之一。
- 干预组1为Communication Bridge™,基于交流参与治疗模式的二元干预,纳入显著训练刺激。
- 对照组为基于损伤治疗模式的非二元干预,针对词语提取和语言产生,采用固定刺激。
- 参与者将在12个月内完成两个治疗阶段, outcomes在基线、每个治疗阶段及入组后12个月测量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Primary progressive aphasia (PPA) is a clinical dementia syndrome. Impairments in language (speaking, reading, writing, and understanding) are the primary and persistent symptoms. These impairments progress insidiously and devastate communication confidence, participation, and quality of life for persons living with PPA. Currently, there are no effective disease modifying treatments for PPA. Speech-language interventions hold promise for mitigating communication challenges and language symptoms. However, evidence regarding their efficacy in PPA is of low quality and there are currently no rigorous randomized trials. METHOD: Communication Bridge™-2 (CB2) is a Stage 2, superiority, single-blind, randomized, parallel group, active-control, behavioral clinical trial delivered virtually within a telehealth service delivery model to individuals with PPA. Ninety carefully characterized participants with clinically confirmed PPA will be randomized to one of two speech-language intervention arms: (1) Communication Bridge™ a dyadic intervention based in communication participation therapy models that incorporates salient training stimuli or (2) the control intervention a non-dyadic intervention based in impairment therapy models addressing word retrieval and language production that incorporates fixed stimuli. The superiority of Communication Bridge™ over the Control arm will be evaluated using primary outcomes of communication confidence and participation. Other outcomes include accuracy for trained words and scripts. Participants complete two therapy blocks over a 12-month period. Outcomes will be measured at baseline, at each therapy block, and at 12 months post enrollment. DISCUSSION: The CB2 trial will supply Level 2 evidence regarding the efficacy of the Communication Bridge™ intervention delivered in a telehealth service delivery model for individuals with mild to moderate PPA. An important by-product of the CB2 trial is that these data can be used to evaluate the efficacy of speech-language interventions delivered in both trial arms for persons with PPA. The impact of these data should not be overlooked as they will yield important insights examining why interventions work and for whom, which will advance effectiveness trials for speech-language interventions in PPA. TRIAL REGISTRATION: ClinicalTrials.gov NCT03371706 . Registered prospectively on December 13, 2017.
引用
- Roberts AC, Rademaker AW, Salley EA, et al. Communication Bridge™-2 (CB2): an NIH Stage 2 randomized control trial of a speech-language intervention for communication impairments in individuals with mild to moderate primary progressive aphasia. Trials. 2022. PMID: 35698099. doi:10.1186/s13063-022-06162-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。